Market accessCompany release

Edesa licenses ARDS antibody paridiprubart to Kyorin for Japan in deal worth over $140m

🇺🇸 Edesa Biotech, Inc. (EDSA) · Mon 09 Nov 2026

Edesa Biotech grants Kyorin Pharmaceutical exclusive Japanese rights to its anti-TLR4 antibody for acute respiratory distress syndrome, with $12m upfront and further milestones and royalties.

Edesa Biotech and Kyorin Pharmaceutical have signed an exclusive collaboration and license agreement under which Kyorin will develop and commercialise paridiprubart in Japan for acute respiratory distress syndrome (ARDS). The agreement was signed on 9 November 2026. Paridiprubart is an anti-TLR4 antibody.

Edesa will receive $12m upfront. It is also eligible for milestone payments of up to about $134m, plus tiered double-digit royalties on sales. Edesa will supply the product to Kyorin.

The agreement also gives Kyorin a right of first negotiation for paridiprubart in acute kidney injury. The announcement does not describe the terms of any such future deal.

The deal does not change the product's regulatory status in Japan. Approval and National Health Insurance (NHI) pricing in Japan are still to come.

What it means for your team

  • Paridiprubart has no Japanese approval or NHI price yet, so any Japanese launch depends on future regulatory and reimbursement decisions.
  • Edesa will supply the product, so supply-chain and quality arrangements between the two companies will matter as development progresses.
  • Kyorin's right of first negotiation in acute kidney injury suggests the partnership could widen beyond ARDS, but no terms have been disclosed.

Company's press release (SEC filing): Edesa Biotech, Inc. ↗

Article written by VigiEye from the official source (Edesa Biotech, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Market access All →